Skip to main content
. 2022 Sep 2;11(17):5196. doi: 10.3390/jcm11175196

Table 3.

CD44, MMP-2, and MMP-9 immunoreactivity of papillary renal cell carcinoma.

Overall Immunohistochemical Score CD44 MMP-2 MMP-9
Group 1 (low expression) (n (%)) 28 (68.29%) 27 (65.85%) 31 (75.61%)
Group 2 (moderate expression) (n (%)) 8 (19.51%) 11 (26.83%) 6 (14.63%)
Group 3 (high expression) (n (%)) 5 (12.20%) 3 (7.32%) 4 (9.76%)